Daily Pharma News - 27 September 2026

India's pharma PLI schemes draw Rs 46,744 crore investment, Rs 4 lakh crore sales (INDIA - TrialMedPath, PIB/Dept. of Pharmaceuticals release)

The Department of Pharmaceuticals' 25 September release confirms that India's three pharma Production Linked Incentive (PLI) schemes have outperformed their investment targets, drawing Rs 46,744 crore in investment alongside nearly Rs 4 lakh crore in sales. Thirty-nine bulk-drug projects covering 28 APIs have been commissioned under the scheme for bulk drugs, while the medical-device PLI scheme has added 57 indigenous devices to domestic manufacturing - including MRI machines and CT scanners.

For pharmacy students, this is a live case study of industrial policy in action: the PLI schemes were designed to reduce India's dependence on imported APIs and high-value devices, and the numbers now show the shift happening in real time.

CDSCO flags Telma AM as suspected spurious; 220 batches fail quality tests (INDIA - The South First)

CDSCO's August 2026 quality alert, reported on 26 September, flagged a Telma AM batch as suspected spurious after the labelled manufacturer denied producing it, and listed 220 batches of medicines, injectables and medical devices as "not of standard quality". Telma AM (telmisartan + amlodipine) is a widely prescribed antihypertensive, making the alert especially significant for patient safety.

This is a reminder of why drug quality control and pharmacovigilance matter as much as drug discovery - spurious and substandard medicines remain a real-world problem, and the CDSCO alert system is the first line of defence. Students should study how to spot, report, and differentiate spurious, substandard, and counterfeit products.

Hyderabad 'virtual API' firm HRV Pharma eyes Rs 800 crore IPO (SOUTH INDIA - The Economic Times)

HRV Pharma, a Hyderabad-based "virtual" bulk-drug company that operates without owning manufacturing plants, has hired ICICI Securities and Equirus as bankers for an IPO expected to raise over Rs 800 crore, with a draft red herring prospectus (DRHP) likely in the first half of 2027. The virtual pharma model - focused on process development, outsourcing, and contract manufacturing networks - has been gaining traction in India's API sector.

The story is worth watching because it signals investor confidence in asset-light, innovation-led API business models in India, and it connects directly to the PLI story above: policy tailwinds plus capital markets are pulling the Indian bulk-drug industry into a new phase.

China NMPA approves Peijia's paclitaxel-coated intracranial balloon catheter (CHINA - Minichart)

On 25 September, China's National Medical Products Administration (NMPA) approved Peijia Medical's SeQuent Please CIS - a paclitaxel drug-coated intracranial balloon catheter based on B. Braun technology - for treating intracranial atherosclerotic stenosis. Drug-coated balloons deliver an anti-proliferative drug (here, paclitaxel) directly to the vessel wall during angioplasty, reducing restenosis without leaving a permanent implant.

This approval highlights the steady expansion of interventional neurology devices and the growing Chinese capability in advanced drug-device combination products - a category pharmacy students will encounter increasingly in hospital practice.

Russia's Nanolek registers 23-valent pneumococcal vaccine Pnevnanol 23 (RUSSIA - GxP News)

Russian manufacturer Nanolek has registered Pnevnanol 23, the country's second 23-valent pneumococcal polysaccharide vaccine, indicated for adults aged 50 and above and children aged 2 to 18. Supplies are expected to begin in Q4 2026, following full-cycle clinical trials conducted in both Russia and China. Polysaccharide vaccines cover 23 serotypes of Streptococcus pneumoniae, the bacterium behind pneumonia, meningitis, and sepsis.

Pneumococcal vaccines are core immunisation-syllabus material, and a new domestic registrant in Russia - tested across two countries - is a good example of how national self-sufficiency goals shape vaccine markets.

FDA approves AbbVie's Juvmo, a once-daily pill for Parkinson's disease (WORLD - Khaleej Times via Reuters)

On 25 September, the US FDA approved tavapadon, marketed as Juvmo, as a once-daily oral dopamine-mimicking pill for adults with Parkinson's disease. The approval follows AbbVie's $8.7 billion acquisition of Cerevel Therapeutics, and AbbVie is targeting more than $5 billion in combined Parkinson's franchise sales. A once-daily dopamine receptor agonist offers simpler dosing and potentially smoother motor control compared with multiple-daily regimens.

For students of pharmacology, tavapadon is a timely illustration of dopamine-receptor pharmacology moving from theory to bedside - and of how big-ticket M&A directly fuels late-stage pipelines.

Xenon submits FDA NDA for azetukalner in focal seizures (WORLD - NeurologyLive)

Xenon Pharmaceuticals has submitted a New Drug Application (NDA) to the US FDA for azetukalner (XEN1101) as add-on therapy for focal seizures in adults, supported by phase 3 X-TOLE2 data. If approved, azetukalner would become the first KV7 potassium channel opener for epilepsy - a genuinely new mechanism of action in a field that has waited decades for one. KV7 channel openers stabilise neuronal membranes by enhancing the M-current, reducing hyperexcitability.

This is a textbook example of mechanism-based drug development: understanding ion-channel physiology opened an entirely new therapeutic class. Watch this one closely - it may redefine add-on therapy in focal epilepsy.

Conclusion

Today's news tells a single coherent story: self-reliance and innovation are reshaping pharma on every front. India's PLI numbers and the HRV Pharma IPO show domestic manufacturing moving from ambition to capital-backed reality; CDSCO's quality alert reminds us that quality systems must grow as fast as manufacturing; and the approvals for Juvmo, azetukalner, SeQuent Please CIS, and Pnevnanol 23 show regulators across the US, China, and Russia clearing genuinely new science for patients. For pharmacy students, the takeaway is clear: keep one eye on policy and industry (PLI, CDSCO, IPOs) and the other on pharmacology (KV7 openers, dopamine agonists, drug-coated devices) - the syllabus and the newsroom are covering the same story from opposite ends.

References

← All daily news